Smith, Tyrel T <br/><br/>
Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors.  [electronic resource] 

 -  The Journal of clinical investigation  Jun 2017 
 - 2176-2191 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1558-8238 
<br/><br/><label>Standard No.: </label>10.1172/JCI87624  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adoptive Transfer<br/>Animals<br/>Antigen-Presenting Cells--physiology<br/>Antineoplastic Agents--administration & dosage<br/>Biopolymers--administration & dosage<br/>Carcinoma, Pancreatic Ductal--immunology<br/>Cell Line, Tumor<br/>Cyclic GMP--administration & dosage<br/>Drug Carriers--administration & dosage<br/>Female<br/>Implants, Experimental<br/>Melanoma, Experimental--immunology<br/>Membrane Proteins--agonists<br/>Mice, Inbred C57BL<br/>Mice, Transgenic<br/>Neoplasm Transplantation<br/>Pancreatic Neoplasms--immunology<br/>T-Lymphocytes--physiology